drugset / Trial / NCT01527825

Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women

NCT01527825

Phase 3 Completed 800 enrolled University of Witwatersrand, South Africa
RandomizedParallel-groupTriple-blindPrevention

Summary

The overall aim of this project is to evaluate the safety and immunogenicity of 3 different dosing options of trivalent influenza vaccine (TIV) vaccination of HIV-infected pregnant women: single dose, double dose (at same time point) and two-doses (1 month apart).

Timeline

Start
2012-09
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine 0.5 ml

Indications